Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Paclitaxel 19pembrolizumab 16Carboplatin 12Bevacizumab 8lenvatinib 6rucaparib 5Nivolumab 5Megestrol Acetate 5Radiation 4Indocyanine Green 4Gemcitabine 4Cisplatin 4tisotumab vedotin 3temsirolimus 3Sirolimus 3Sentinel Lymph Node Biopsy 3Magnetic Resonance Spectroscopy 3Doxorubicin 3olaparib 2niraparib 2ixabepilone 2iso-sulfan blue 2irosustat 2epacadostat 2durvalumab 2copanlisib 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Neoplasms × Pharmacogenomic Variants × Clear all
NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 13 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡